Pharmaceutical Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X
Analysis

Blocking generic competition: will naming and shaming work?

The US Food and Drug Administration (FDA) has publicly listed the names of nearly 40 pharma companies that may have been denying access to reference samples for generic drug manufacturers, thereby delaying generic competition. Is this ‘name and shame’ strategy justified, and just how big is the issue of pharma companies holding back reference samples from generic competitors after patent expiry?

Go Top